Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity
- 주제(키워드) gefitinib , hepatotoxicity , H2 antagonist , proton pump inhibitor , EGFR mutation
- 주제(기타) Pharmacology & Pharmacy
- 설명문(일반) [Cho, Soyeon; Yee, Jeong; Rhie, Sandy Jeong; Gwak, Hye Sun] Ewha Womans Univ, Coll Pharm, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Cho, Soyeon; Yee, Jeong; Rhie, Sandy Jeong; Gwak, Hye Sun] Ewha Womans Univ, Div Life & Pharmaceut Sci, 52 Ewhayeodae Gil, Seoul 03760, South Korea; [Kim, Jae Youn] Asan Med Ctr, Dept Pharm, Seoul, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 WILEY
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000150103
- 본문언어 영어
- Published As http://dx.doi.org/10.1002/jcph.1010
초록/요약
Gefitinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) patients. Severe hepatotoxicity was observed, but only a few cases have been reported on the hepatotoxicity of gefitinib. This study aimed to investigate the association between gefitinib-induced hepatotoxicity and various factors including concomitant medications in lung cancer patients. From January 2013 to December 2014, a retrospective study was performed with NSCLC patients who were treated with gefitinib. Associations between hepatotoxicity and various factors including concomitant drugs were analyzed. Based on multivariate models, it was found that H2 antagonists, proton pump inhibitors (PPIs), and H2 antagonists or PPIs increased hepatotoxicity by about 1.5- to 1.7-fold. Patients younger than 65 years showed 1.6 times higher hepatotoxicity than those older than 65 years. Patients with EGFR mutations had around 2-fold higher hepatotoxicity, and the percentage of incidence of hepatotoxicity because of exon 19 deletion was 32.7%. Our study showed that anti-acid-secreting agents in addition to age younger than 65 years and EGFR mutation were associated with gefitinib-induced hepatotoxicity. Thus, close monitoring of liver function is recommended, especially for patients using anti-acid-secreting agents.
more